A systematic review of the therapeutic effect of platelet-rich plasma for treating traumatic brain injury

Abstract

Abstract Traumatic brain injury (TBI) is the leading cause of death and disability worldwide and thus a significant public health concern. It can result in a range of physical, cognitive, and emotional impairments, which can significantly impact the quality of life of affected individuals and their families. Despite advances in the management of TBI, no effective treatment fully restores neurological function. Platelet-rich plasma (PRP) is a promising therapeutic approach for the treatment of TBI that has gained increasing attention in recent years. PRP is a blood product containing high concentration of platelets rich in growth factors and other bioactive molecules that can promote tissue repair and regeneration. PRP has been used in various clinical settings to accelerate healing and reduce inflammation, and there is growing evidence that it may have therapeutic benefits for TBI. This study seeks to gather evidence-based information on the therapeutic effect of PRP in the treatment of TBI. This protocol will follow the criteria of the Preferred Reporting Items for Systematic Reviews and Meta-Analysis [PRISMA] guideline 2020. In this review, we determined four primary central databases as sources of information: PubMed, EMBASE, SCOPUS, and Cochrane Central Register of Controlled Trails. This Project was registered on the International Prospective Register of Systematic Reviews [PROSPERO]. Ethics and dissemination: Ethical approval for this study was not needed as we used alread y published studies to run this current study. Study findings will be published in journals and presented at conferences for broader dissemination. PROSPERO Registration N°: CRD42023426358.